Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2010

01-12-2010 | Epidemiology

Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis

Authors: Xiaoan Liu, Zhanwei Wang, Jinhua Yu, Gang Lei, Shui Wang

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

Interleukin-1β (IL-1β), which is involved in inflammatory and immunological responses, plays an important role in the development and progression of breast cancer. Three functional single nucleotide polymorphisms (SNPs) identified in IL-1β gene are thought to influence breast cancer risk. The results of the association between IL-1β polymorphisms and breast cancer remain inconsistent. Therefore, we conducted a meta-analysis of eight case–control studies with rs1143627 (T > C), rs16944 (C > T), and rs1143634 (C > T). We found that the variant CC genotype of rs1143627 was associated with a significantly increased breast cancer risk (CC vs. TT: OR = 1.37, 95% CI = 1.10–1.70, P = 0.22 for heterogeneity; the recessive model CC vs. TT/TC: OR = 1.40, 95% CI = 1.17–1.67, P = 0.49 for heterogeneity). For rs16944 (C > T) and rs1143634 (C > T), no significant associations were found in all genetic models. In conclusion, the present meta-analysis suggests that rs1143627 is associated with breast cancer risk.
Literature
1.
2.
Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB, Atkin SL (1999) Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. Int J Oncol 15:1251–1254PubMed
3.
Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, Okai T (2002) The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 49:371–377CrossRefPubMed
4.
Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F (2001) Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J Am Coll Cardiol 38:712–717CrossRefPubMed
5.
Eklund C, Jahan F, Pessi T, Lehtimaki T, Hurme M (2003) Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw 14:168–171PubMed
6.
Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396–402CrossRefPubMed
7.
Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Inoue M, Hirose K, Tajima K (2002) Significant reduction in breast cancer risk for Japanese women with interleukin 1B–31 CT/TT relative to CC genotype. Jpn J Clin Oncol 32:398–402CrossRefPubMed
8.
Akisik E, Dalay N (2007) Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer. J Clin Lab Anal 21:97–102CrossRefPubMed
9.
Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188CrossRefPubMed
10.
Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res 11:5718–5721CrossRefPubMed
11.
Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, Ahn SH, Yoo KY, Hirvonen A, Kang D (2006) Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women. Breast Cancer Res Treat 96:197–202CrossRefPubMed
12.
Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, Qin J, Gao J, Ma H, Wei Q, Shen H (2006) Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer 118:2554–2558CrossRefPubMed
13.
Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRefPubMed
14.
Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L (2005) Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16:253–260PubMed
15.
Wang Z, Fu Y, Tang C, Lu S, Chu W (2009) SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0648-y
16.
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMed
17.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
18.
19.
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed
20.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402CrossRefPubMed
Metadata
Title
Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis
Authors
Xiaoan Liu
Zhanwei Wang
Jinhua Yu
Gang Lei
Shui Wang
Publication date
01-12-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0910-3

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue

Brief Report

Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report

Preclinical study

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

Clinical trial

A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results

Brief Report

Breast-conserving therapy after previous irradiation for lymphoma

Letter to the Editor

Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer

Preclinical study

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits